Re-shaping clinical practice in neuroendocrine tumours (NETs)


Session type:

John Primrose1, Juan Valle2
1University of Southampton, Southampton, UK, 2The Christie NHS Foundation Trust, Manchester, UK


Neuroendocrine tumours (NETs) are considered rare tumours; however, due to their indolent course they are the second commonest gastrointestinal (GI) malignancy by prevalence. Improved understanding of the biology of NET behaviour twinned with imaging and therapeutic advances are changing the paradigm of clinical practice. In this session we will focus on emerging molecular insights gained from circulating biomarkers; explore the concept of ‘Theranostics' (molecular imaging leading to therapy) when applied to NETs and review the relative merits of systemic therapies with specific attention to optimal use and sequencing of available treatments for patients with advanced disease.